Advisers & FriendsDerick H. Lau, M.D.
|
Clinical/Research InterestsDr. Lau is a clinical scientist and cancer expert whose work involves patient care and translational research. His clinical specialty is the management of lung, esophageal and head/neck cancers, especially the development of new treatments. He is currently investigating novel molecular targeting therapy in cancer models. |
Title: |
Professor Associate Director of Fellowship Program |
Specialty: |
Hematology and Oncology |
Center/Program Affiliation: |
UC Davis Cancer Center |
Address: |
UC Davis Cancer Center 4501 X St., Suite 3017 Sacramento, CA 95817 |
Phone: |
(916) 734-3700 |
Other Languages: |
Cantonese, English, Mandarin |
Education: |
University of Missouri, Columbia, School of Medicine Columbia, Missouri M.D. 1984 |
|
UC Davis Davis, California B.S. 1972 |
|
Residency: |
San Joaquin Valley Program Fresno, California 1984-87 Internal Medicine University of California, San Francisco, San Joaquin Valley Program San Francisco, CA 1984-87 Internal Medicine |
Fellowships: |
UC Davis Medical Center Sacramento, CA 1990-91 Internal Medicine, Hematology-Oncology Stanford University Stanford, California 1987-90 Clinical Pharmacology/Medical Oncology |
Board Certifications: |
American Board of Internal Medicine, Medical Oncology, 1991 American Board of Internal Medicine, 1987 |
Professional Memberships: |
American Association of Cancer Research American Medical Association American Society of Clinical Oncology Southwest Oncology Group |
Select Recent Publications: |
Wang H, Ryu J, Gandara D, Bold R, Urayama S, Goldberg Z, Tanaka M, Follette D, Narayan S and Lau D. A Phase II Study of Paclitaxel, Carboplatin and Radiation with or without Surgery for Esophageal Cancer. J Thorac Oncol 2:153-157, 2007. Lara PN, J Longmate, M Koczywas, HJ Lenz, DI Quinn, AM Davies, DHM Lau, PH Gumerlock, JH Doroshow, D Schenkein, O Kashala, DR Gandara. Phase-I study of bortezomib plus docetaxel in advanced non-small-cell lung cancer and other solid tumors. Journal of Thoracic Oncology, 1(2):126-134. West HL, WA Franklin, J McCoy, P Gumerlock, R Vance, DHM Lau, K Chansky, JJ Crowley, DR Gandara. Gefitinib (Iressa) therapy in advanced bronchioloalveolar carcinoma (BAC): Southwest Oncology Group Study S0126. J Clin Oncol (In press). Lau D, L Guo, R Liu, J Marik, K Lam. Peptide ligands targeting integrin a3b1 in non-small cell lung cancer. (In press) Lau D, M Huynh, J Johl, P Lara, D Gandara. A population-based approach for phase-I clinical trials. (In preparation) Lau D, J Johl, M Huynh, A Davies, M Tanaka, P Lara, D Gandara. A phase-I trial of intrapatient dose-escalation of irinotecan and epirubicin. (In preparation) Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 6:281-286, 2005.Lau D, Linlang Guo, Ruiwu Liu, Jan Marik and Kit Lam. Peptide Ligands Targeting Integrin ?3?1 in Non-small Cell Lung Cancer. Lung Cancer 52:291-297, 2006. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 6:281-286, 2005.Lau D, Linlang Guo, Ruiwu Liu, Jan Marik and Kit Lam. Peptide Ligands Targeting Integrin ?3?1 in Non-small Cell Lung Cancer. Lung Cancer 52:291-297, 2006. Huynh M, K Chee, DH Lau. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother. Aina OH, J Marik, R Liu, DH Lau, KS Lam. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther, 4:806-813. |
To see if Derick H. Lau is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.